Full Breakdown
Supreme Court Preserves Mail Access to Mifepristone
5/15/2026, 2:57:22 AM
Core Ruling
On May 14, 2026 the Supreme Court issued an unsigned emergency order preserving nationwide mail-order and telehealth dispensing of mifepristone, blocking the 5th Circuit’s May 1 decision that would have required in-person provision.
Background
The FDA removed the in-person dispensing rule for mifepristone in 2021 and fully eliminated it in 2023, enabling telehealth prescriptions and mail delivery. Louisiana sued, arguing the change violates the 1873 Comstock Act and undermines its near-total abortion ban after Dobbs restored state authority.
Data & Statistics
Medication abortions made up about two-thirds (? 63 %) of U.S. abortions in 2023. Over one-quarter of all abortions are obtained via telehealth. Data show five deaths per 1 million mifepristone users.
Why It Matters
The order keeps the method of pregnancy termination available in states that ban clinic abortions, preserving access for patients in remote areas and underscoring the clash between federal drug authority and state abortion regulation.
Official Statements & Responses
Danco spokesperson Abby Long said the firm is “pleased that a safe and effective drug Americans depend on will continue to be available.” GenBioPro CEO Evan Masingil pledged to keep supplying the medication. Louisiana Attorney General Liz Murrill called the decision “shocking” and vowed to keep fighting. Nancy Northup of the Center for Reproductive Rights called the order “a relief for patients but no peace of mind.”
Criticism & Opposition
Justices Clarence Thomas and Samuel Alito dissented, invoking the Comstock Act and calling mail distribution a “criminal enterprise” that harms the state’s abortion ban. Louisiana and anti-abortion groups argue that mailed pills bypass the ban and pose safety risks despite FDA data.
Conflicting Reports & Gaps
Louisiana asserts up to 1,000 abortions per month result from mailed pills. Anti-abortion activists contend the figure is higher, but they do not cite a specific number. Independent data show medication abortions remain a minority of total abortions in the state. Opponents also claim the FDA’s safety review is incomplete, a point not yet resolved by the courts.
Verbatim Quotes
- “Applicants are not entitled to a stay of an adverse court order based on lost profits from their criminal enterprise.” — Justice Clarence Thomas
- “The Court’s unreasoned order granting stays in this case is remarkable. What is at stake is the perpetration of a scheme to undermine our decision” — Justice Samuel Alito
- “We are pleased that a safe and effective drug Americans depend on will continue to be available while this litigation proceeds,” — Abby Long, Danco spokesperson
- “It’s shocking that the Supreme Court would block this common-sense return to medically ethical practices and oversight,” — Liz Murrill, Louisiana Attorney General
What’s Next
The case returns to the 5th Circuit for a merits hearing, and the FDA’s ongoing safety review may prompt further regulatory action. Both parties have signaled intent to pursue additional appeals, keeping the issue on the national agenda.
